Novo Nordisk has transferred global rights to a clinical-stage Parkinson’s cell therapy to Cellular Intelligence, a startup focused on engineering cell behavior. The Danish pharmaceutical giant took an equity stake in the company and retained milestone and royalty rights, though financial terms were not disclosed.
Cellular Intelligence, formerly known as Somite AI, is developing foundation models that predict cell behavior. The therapy, which targets Parkinson’s disease, has already entered clinical testing under Novo Nordisk’s oversight. Specific trial phase, patient population, efficacy rates, and safety profiles were not detailed in the announcement.
The deal provides Cellular Intelligence with a late-stage asset to advance through its AI-driven platform. The startup has raised over $60 million from investors including Khosla Ventures, AMD Ventures, CZI, and SciFi VC, funds that will likely support further clinical development and model training.
For Novo Nordisk, the transaction offloads a non-core asset while preserving upside through royalties and milestones. The move aligns with a broader industry trend of large pharma companies spinning out early-stage programs to nimble startups with specialized AI capabilities.
The arrangement underscores growing interest in computational biology approaches to neurodegenerative diseases. However, Parkinson’s cell therapies face significant hurdles in manufacturing, delivery, and long-term efficacy, and no such treatment has yet received regulatory approval in any major market.